Korneva V A, Kuznetsova T Yu, Bogoslovskaya T Yu, Polyakov D S, Vasilyev V B, Orlov A V, Mandelshtam M Yu
Department of Faculty Therapy, Phthisiology, Infectious Diseases and Epidemiology, Institute of Medicine, Petrozavodsk State University, 33 Lenin Str., Petrozavodsk, Republic of Karelia 185910, Russia.
Department of Molecular Genetics, Institute of Experimental Medicine, 12 Pavlov Street, St. Petersburg 197376, Russia.
Cholesterol. 2017;2017:9375818. doi: 10.1155/2017/9375818. Epub 2017 Mar 28.
Familial hypercholesterolaemia (FH) is a rare disease that tends to be diagnosed lately. In Russia, the genetic and phenotypic characteristics of the disease are not well defined. We investigated 102 patients with definite FH. In 52 of these patients (50.9%) genetic analysis was performed, revealing pathogenic mutations of the low density lipoprotein (LDL) receptor gene in 22 patients. We report here five mutations of the LDL receptor gene found in the Karelian FH sample for the first time. The detection rate of mutations in definite FH patients was 42.3%. Two groups of patients with a definite diagnosis of FH according to the Dutch Lipid Clinic Network criteria were compared: the first group had putatively functionally important LDL receptor gene mutations, while in the second group LDL receptor gene mutations were excluded by single-strand conformation polymorphism analysis. Total and LDL cholesterol levels were higher in the group with LDL receptor mutations compared to the mutation-free population. The frequency of mutations in patients with LDL cholesterol > 6.5 mmol/L was more than 3 times higher than that in patients with LDL < 6.5 mmol/L. Total and LDL cholesterol levels and the frequency of coronary heart disease and myocardial infarction were higher in the group with definite FH compared to groups with probable and possible FH. Cholesterol figures in FH patients of different age and sex from the Karelian population were comparable.
家族性高胆固醇血症(FH)是一种罕见疾病,往往在较晚时才被诊断出来。在俄罗斯,该疾病的遗传和表型特征尚不明确。我们对102例确诊为FH的患者进行了调查。其中52例患者(50.9%)进行了基因分析,发现22例患者存在低密度脂蛋白(LDL)受体基因的致病突变。我们在此首次报告在卡累利阿FH样本中发现的5种LDL受体基因突变。确诊FH患者的突变检出率为42.3%。根据荷兰脂质诊所网络标准,对两组确诊为FH的患者进行了比较:第一组有推测具有功能重要性的LDL受体基因突变,而第二组通过单链构象多态性分析排除了LDL受体基因突变。与无突变人群相比,LDL受体基因突变组的总胆固醇和LDL胆固醇水平更高。LDL胆固醇>6.5 mmol/L的患者的突变频率比LDL<6.5 mmol/L的患者高出3倍多。与可能患有FH和疑似患有FH的组相比,确诊为FH的组的总胆固醇和LDL胆固醇水平以及冠心病和心肌梗死的发生率更高。卡累利阿人群中不同年龄和性别的FH患者的胆固醇数值具有可比性。